 beneﬁt of FS for
treatment of superﬁcial venous disease, with minimal
side effects. While in theory felt to be safer, there is
limited data that directly compares the use of CO2 or
CO2/O2-based foam to room air when treating with
foam sclerosants.
Evidence. UGFS has been shown to be safe and effective for the treatment of superﬁcial venous disease, and
it is currently recommended for treatment of reticular